Results 111 to 120 of about 1,010,797 (263)

Retractions in Rheumatology: Trends, Causes, and Implications for Research Integrity

Arthritis Care &Research, EarlyView.
Objective We aimed to describe the trends and main reasons for study retraction in rheumatology literature. Methods We reviewed the Retraction Watch database to identify retracted articles in rheumatology. We recorded the main study characteristics, authors’ countries, reasons for retraction, time from publication to retraction, and trends over time ...
Anna Maria Vettori, Michele Iudici
wiley   +1 more source

Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA‐B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers

Arthritis Care &Research, EarlyView.
Objective The American College of Rheumatology recommends HLA‐B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and African American/Black patients, due to their increased risk for severe hypersensitivity reactions. However, testing rates remain low at many health care facilities.
Abimbola Fadairo‐Azinge, Gabriela Schmajuk, Sristi Sharma, Colleen P. Flanagan, Sara Faghihi‐Kashani, Ning Zhang, Mary A. Whooley   +6 more
wiley   +1 more source

Safety assessment of temporal interference stimulation. [PDF]

Front Neurosci
Hou R, Acerbo E, Yoshimoto R, Laxpati NG, Berglund K, Gutekunst CA.   +5 more
europepmc   +1 more source

Safety Assessment

, 2018
Alessandro Freddi, Mario Salmon
openaire   +2 more sources

FDA roadmap to reducing animal testing: a regulatory and scientific paradigm shift in nonclinical safety assessment. [PDF]

Stem Cell Res Ther
Lei Y, Tuan RS, Li ZA.
europepmc   +1 more source

Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus—A Systematic Review and Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta‐analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE ...
Zahraa Qamhieh, Dalia Sriwi, Callie Saric, Tripti Singh, Christie M. Bartels, Shivani Garg   +5 more
wiley   +1 more source

Mars sample return campaign: biological risk and a proposed sample safety assessment protocol. [PDF]

Appl Environ Microbiol
McDonnell G, Teece BL, Mackelprang R, Cressie N, McQuiston JR, Mayhew LE, Steele A, Siljeström S, Ahern BM, Baird N, Davis RE, French KL, Glamoclija M, Graham H, Hummel KB, Page W, Pearce N, Regberg A, Relman D, Sephton MA, Sherwood Lollar B, Vanhomwegen J, Wilhelm MB, Shirey B, Beaty DW.   +24 more
europepmc   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Real‐World Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study

Arthritis Care &Research, EarlyView.
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel, Fauzia Hollangel, Caroline Packee, Amita Kapoor, Brad Rovin, Nathalie Costedoat‐Chalumeau, Shivani Garg   +6 more
wiley   +1 more source

Safety Assessment of Perioperative Pain Medications for Children: Variation in Opioid Prescribing at Discharge. [PDF]

Ann Surg Open
Perez MN, Huang L, Schäfer WLA, Lehane AJ, Smith CJ, Kennedy S, Holl JL, Aprahamian CJ, Pillai SB, Slater BJ, Raval MV.   +10 more
europepmc   +1 more source